product summary
Loading...
company name :
Tocris Bioscience
product type :
chemical
product name :
JNJ 10198409
catalog :
6976
quantity :
10 mg (also 50 mg)
price :
225 USD
more info or order :
image
image 1 :

Cat.No. 6976 - JNJ 10198409 C18H16FN3O2 CAS No. 627518-40-5
product information
brand :
Tocris
master code :
6976
SKU :
6976/10
product name :
JNJ 10198409
description :
Potent PDGFR and PDGFR inhbitor; also inhibits c-Abl, Lck, c-Src and Fyn kinases
target :
PDGF Receptor Inhibitors
category :
Small Molecules
unit size :
10 mg (also 50 mg)
purity :
98%
observed molecular weight :
325.34
url print :
?utm_source=distributor&utm_medium=referral&utm_campaign=product&utm_term=smallmolecules
details of functionality :
Potent platelet-derived growth factor receptor (PDGFR) inhibitor (IC50 values are 4.2 and 45 nM for PDGFR and PDGFR , respectively). Also inhibits c-Abl, Lck, c-Src and Fyn kinases (IC50 values are 22, 100, 185 and 378 nM respectively). Displays antiproliferative activity in multiple tumor cell lines. Accelerates down regulation of fibroblast genes in reprogramming of human fibroblasts into functional cardiomyocytes, within 9C cocktail.
catalog number base :
6976
product keywords :
JNJ10198409 stem cell reprogramming 9C cocktail cardiomyocytes myocytes platelet-derived growth factor receptor alpha beta inhibitors inhibits PDGFR PDGFRb PDGFRa PDGFR Src Kinases Other Kinases Stem Cell Reprogramming 6976,
extended description :
Potent PDGFR and PDGFR inhbitor; also inhibits c-Abl, Lck, c-Src and Fyn kinases
chemical name text :
N-(3-Fluorophenyl)-1,4-dihydro-6,7-dimethoxyindeno[1,2-c]pyrazol-3-amine
formula :
C 18 H 16 FN 3 O 2
formula text :
C18H16FN3O2
cas num :
627518-40-5
2020 USD :
225
2021 USD :
225 USD
storage :
Store at -20°C
more info or order :
company information

Tocris Bioscience
The Watkins Building
Atlantic Road
Avonmouth, Bristol
BS11 9QD
Atlantic Road
Avonmouth, Bristol
BS11 9QD
info@bio-techne.com
https://www.tocris.com800-343-7475
headquarters: UK
browse more products
questions and comments